(Q40017560)

16 September 2017

title

Can rate of brain atrophy in multiple sclerosis be explained by clinical and MRI characteristics? (English)

1 reference

ORCID Public Data File 2021

16 September 2017

0 references

1 reference

author name string

T Korteweg

1

1 reference

16 September 2017

M Rovaris

2

1 reference

16 September 2017

V Neacsu

3

1 reference

16 September 2017

M Filippi

4

1 reference

16 September 2017

G Comi

5

1 reference

16 September 2017

B M Uitdehaag

6

1 reference

16 September 2017

D L Knol

7

1 reference

16 September 2017

C H Polman

8

1 reference

16 September 2017

F Barkhof

9

1 reference

16 September 2017

H Vrenken

10

1 reference

16 September 2017

MAGNIMS collaboration

11

1 reference

16 September 2017

publication date

17 December 2008

1 reference

Multiple Sclerosis Journal

16 September 2017

published in

1 reference

16 September 2017

volume

15

1 reference

16 September 2017

issue

4

1 reference

16 September 2017

page(s)

465-471

1 reference

Measuring brain atrophy in multiple sclerosis

16 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1352458508100505

Magnetic resonance imaging measures of brain atrophy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508100505

Normal-appearing white and grey matter damage in MS. A volumetric and diffusion tensor MRI study at 3.0 Tesla.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508100505

Localized grey matter damage in early primary progressive multiple sclerosis contributes to disability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508100505

Whole-brain T1 mapping in multiple sclerosis: global changes of normal-appearing gray and white matter.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508100505

Diagnostic criteria for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508100505

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508100505

Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508100505

Defining the clinical course of multiple sclerosis: Results of an international survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508100505

Advances in functional and structural MR image analysis and implementation as FSL

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508100505

Accurate, robust, and automated longitudinal and cross-sectional brain change analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508100505

Eight-year follow-up study of brain atrophy in patients with MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508100505

Determinants of cerebral atrophy rate at the time of diagnosis of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508100505

Longitudinal brain volume measurement in multiple sclerosis: rate of brain atrophy is independent of the disease subtype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508100505

Brain atrophy in clinically early relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508100505

Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the early development of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508100505

A 6-year clinical and MRI follow-up study of patients with relapsing-remitting multiple sclerosis treated with Interferon-beta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508100505

Brain atrophy in multiple sclerosis: impact of lesions and of damage of whole brain tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508100505

Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508100505

21 January 2018

Identifiers

DOI

10.1177/1352458508100505

1 reference

16 September 2017

1 reference